Tridek-One is developing a novel CD31 agonist approach to modulate immune activation for the treatment of autoimmune diseases.
Location: France, Ile-de-France, Paris
Total raised: $17.42M
Investors 1
| Date | Name | Website |
| - | Bioqube Ve... | bioqubeven... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.10.2022 | - | $17.42M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 12.10.2022 | TRIDEK-ONE CLOSES A €16 MILLION FINANCING ROUND TO DEVELOP F... | Paris, France, September 15, 2022 – Tridek-One SAS (the ‘Company’), a leading biotech start- up spec... | bioqubeven... |
| 16.09.2022 | French biotech Tridek-One gets €16 million booster to restor... | Paris-based biotech startup Tridek-One has raised €16 million in funding to speed up its research an... | tech.eu/20... |
| 16.09.2022 | Tridek-One Closes €16M Funding | Tridek-One, a Paris, France-based biotech startup specialized in the research and development of CD3... | finsmes.co... |
| - | TRIDEK-ONE CLOSES A €16 MILLION FINANCING ROUND TO DEVELOP F... | Paris, France, September 15, 2022 – Tridek-One SAS (the ‘Company’), a leading biotech start- up spec... | bioqubeven... |
| - | Tridek-One | “The Future of immunomodulation” | fastfounde... |